Centro De Ingenieria Genetica Y Biotecnologia

Mariela Vazquez Castillo

Gerardo Enrique Guillén Nieto

Gerardo Enrique Guillen Nieto

Jorge Amador Berlanga Acosta

Sonia Gonzalez Blanco

Diana Garcia Del Barco Herrera

Hilda Elisa Garay Perez

Enrique Iglesias Perez

Osmany Guirola Cruz

Vivian Huerta Galindo

Eduardo Pentón Arias

Julio César Aguilar Rubido

Eduardo Penton Arias

Alejandro Miguel Martin Dunn

Danay Cibrian Vera

Yadira Lobaina Mato

Jorge Valdes Hernandez

Manuel Selman-Housein Sosa

Jorge Berlanga Acosta

Ernesto Lopez Mola

Viviana Falcon Cama

Jose Suarez Alba

Julio Cesar Aguilar Rubido

Jorge Agustín Aguiar Santiago

José Suarez Alba

Luis Javier Gonzalez Lopez

Dianne Pupo Gomez

Glay Chinea Santiago

Rocio Garateix Suarez

Osvaldo Reyes Acosta

Karen Alvarez Perez

Gabriel Jesus Marquez Perera

Alexis Yero Diaz

Diana García Del Barco Herrera

This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.

Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis B virus

The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.

Method for controlling fibrosis and other pathological deposits in tissues comprising administering a GHRP-6 composition

Growing community of inventors

Ciudad de la Habana, Cuba

Mariela Vazquez Castillo